Aarti Drugs
Other · 3 quarters tracked · source-linked performance and management context.
Latest revenue
₹721.1 Cr
verified financial record
Quarters tracked
3
source records in the directory
Delivery assessment
0
Across 2 tracked commitments: 0 delivered, 2 missed.
Call date
2026-04-30
latest available source date
Signal trajectory
3 actual quartersCurrent read
0/100
Across 2 tracked commitments: 0 delivered, 2 missed.
Latest source read
What changed this quarter?
Aarti Drugs reported Q4 FY26 consolidated revenue of ₹721.1 crore (+6% YoY) and EBITDA of ₹96.6 crore (13.4% margin). PAT declined 12% YoY to ₹55.3 crore due to elevated costs and ramp-up expenses. The methylamine plant achieved ~40% utilization in Q4, targeting 55-60% in Q1 FY27. Formulation revenue surged 41% YoY to ₹91.3 crore, driven by export growth. Management guided for 8-10% volume growth and 100-200 bps EBITDA margin improvement in FY27, contingent on stable crude prices. Key risks include sustained high crude impacting antibiotic demand and delayed salicylic acid turnaround.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Watch
Revenue
₹721.1 Cr
Source date
2026-04-30
Across the record
Quarter history.
History modules